Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20 Prostatic Neoplasms 7 Triple Negative Breast Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Melanoma 3 Lymphoma 3 Lung Neoplasms 3 Hematologic Neoplasms 3 Endometrial Neoplasms 3 Uterine Cervical Neoplasms 2 Recurrence 2 Neoplasms 2 Multiple Myeloma 2 Locally Advanced (Inoperable) or Metastatic Breast Cancer 2 Leukemia 2 Healthy Participants 2 Disease Progression 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Rectal Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Solid Malignancy, × capivasertib × Clear all

NCT01895946 2016-05-25

OAK

AstraZeneca

Phase 1 Completed

33 enrolled 14 charts

Advanced Solid Malignancy,

Data powered by HemOnc (CC BY 4.0) Colophon ⚡